• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email
    SC 13G/A 1 finsavara.htm 13G HTML File DOCUMENT TYPE SC 13G/A
    TEXT


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    Amendment # 1

    Name of Issuer: SAVARA INC
    _____________________________________________________
    Title of Class
    of Securities: Common Stock

    CUSIP Number: 805111101

    1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON

    Prudential Financial, Inc. 22-3703799

    2.) MEMBER OF A GROUP: (a) N/A
    (b) N/A

    3) SEC USE ONLY:



    4) PLACE OF ORGANIZATION: New Jersey

    NUMBER OF SHARES BENEFICIALLY OWNED BY REPORTING PERSON WITH:

    5) Sole Voting Power: 7,475 See Exhibit A
    6) Shared Voting Power: 7,402,776 See Exhibit A
    7) Sole Dispositive Power: 7,475 See Exhibit A
    8) Shared Dispositive Power: 7,402,776 See Exhibit A

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED: 7,410,251 See Exhibit A

    10) AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES: Not applicable

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 4.50 See Exhibit A

    12) TYPE OF REPORTING PERSON: HC

    ITEM 1(a). NAME OF ISSUER:

    SAVARA INC

    ITEM 1(b). ADDRESS OF ISSUER'S EXECUTIVE OFFICES:

    6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN, TX 78746

    ITEM 2(a). NAME OF PERSON FILING:

    Prudential Financial, Inc.

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    751 Broad Street
    Newark, New Jersey 07102-3777

    ITEM 2(c). CITIZENSHIP:

    New Jersey

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2(e). CUSIP NUMBER:

    805111101

    ITEM 3. The Person filing this statement is a Parent Holding Company as
    defined in Section 240.13d-1(b)(1)(ii)(G) of the Securities Exchange
    Act of 1934.

    ITEM 4. OWNERSHIP:

    (a) Number of Shares
    Beneficially Owned: 7,410,251 See Exhibit A


    (b) Percent of Class: 4.50


    (c) Powers                No. Of Shares
    ----------- --------------------
    Sole power to vote or 7,475 See Exhibit A to direct the vote
    Shared power to vote or 7,402,776 See Exhibit A to direct the vote
    Sole power to dispose or 7,475 See Exhibit A to direct disposition
    Shared power to dispose 7,402,776 See Exhibit A or to direct disposition

    ITEM 5. OWNERSHIP OF 5% OR LESS OF A CLASS:

    Prudential Financial, Inc. through its beneficial ownership of the Item 7 listed entities has ceased to be deemed the beneficial owner of more than 5% of the outstanding Common Stock of this issuer.

    ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF
    ANOTHER PERSON:

    Not Applicable

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE
    SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
    REPORTED ON BY THE ULTIMATE PARENT COMPANY:

    See Exhibit A

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
    MEMBERS OF THE GROUP:

    Not Applicable

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

    Not Applicable

    ITEM 10. CERTIFICATION:

    By signing below, Prudential Financial, Inc. certifies that, to the best of its
    knowledge and belief, the securities referred to above were acquired
    and are held in the ordinary course of business and were not acquired
    and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction
    having that purpose or effect.


    The filing of this statement should not be construed as an admission that
    Prudential Financial, Inc. is, for purposes of Sections 13 or 16 of the Securities
    Exchange Act of 1934, the beneficial owner of such shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief,
    Prudential Financial, Inc. certifies that the information set forth in this
    statement is true, complete and correct.

    PRUDENTIAL FINANCIAL, INC.

    By:RICHARD BAKER
    Second Vice President

    Date:11-14-2024
    As of:9-30-2024

    Exhibit A
    --------------

    ITEM 4. OWNERSHIP:

      Through its parent/subsidiary relationship, Prudential Financial, Inc. may
      be deemed the beneficial owner of the same securities as the Item 7 listed
      subsidiaries and may have direct or indirect voting and/or investment
      discretion over 7,410,251 shares.
      

    These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Prudential Financial, Inc. is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares.




    ITEM 7. IDENTIFICATION/CLASSIFICATION:

    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names:
    

    
    
    Subsidiaries Number of Shares Percentage
    The Prudential Insurance Company of America IC 0 0.00
    Jennison Associates LLC IA 6,732,776 4.09
    PGIM, Inc. IA 670,000 .41
    PGIM Quantitative Solutions LLC IA 7,475 0.00
    PRUCO Securities, LLC IA 0 0.00





    Get the next $SVRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    10/20/2025$7.00Overweight
    Wells Fargo
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    5/16/2023$2.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $SVRA
    SEC Filings

    View All

    SEC Form 424B5 filed by Savara Inc.

    424B5 - Savara Inc (0001160308) (Filer)

    10/30/25 4:43:56 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Savara Inc.

    8-K - Savara Inc (0001160308) (Filer)

    10/30/25 4:26:01 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Savara Inc.

    424B5 - Savara Inc (0001160308) (Filer)

    10/29/25 4:42:04 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Wasfi Yasmine was granted 35,000 shares, increasing direct ownership by 23% to 190,000 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    10/22/25 8:47:47 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Wasfi Yasmine claimed ownership of 155,000 shares (SEC Form 3)

    3 - Savara Inc (0001160308) (Issuer)

    10/22/25 8:44:51 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Savara with a new price target

    Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00

    10/20/25 8:03:17 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00

    8/15/25 9:10:16 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00

    5/29/25 8:15:44 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Savara Announces Participation in Upcoming Investor Healthcare Conferences

    Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Guggenheim 2nd Annual Healthcare Innovation Conference November 10, 2025, 8:30 a.m. ET Jefferies London Healthcare Conference November 19, 2025, 12:00 p.m. GMT The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara  Savara is a clinical stage biopharmaceutical company focused

    11/3/25 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors that so chose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant. The aggregate gross proceeds to Savara from the offering were approximately $149.5 million bef

    10/31/25 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting discounts and commissions, for total gross proceeds of $130.0 million. All of the securities to be sold in the offering are being sold by Savara. Savara also granted the underwriters a 30-day option to purchase up to an additional 4,642,

    10/29/25 9:43:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/2/25 7:59:29 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    4/1/25 7:00:04 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

    Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

    9/24/24 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

     Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

    11/10/22 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Resignation of Chief Medical Officer

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

    8/26/22 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/12/24 10:25:33 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Financials

    Live finance-specific insights

    View All

    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

    6/26/24 6:30:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

    6/25/24 8:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care